TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

AN UNPREDICTABLE AND POTENTIALLY LIFE-THREATENING GENETIC DISEASE

Hereditary angioedema (HAE) is a rare genetic disease that causes recurrent, debilitating, and potentially life-threatening attacks of angioedema in the body. HAE affects about 1 in 50,000 people of all ages.^1,2

An accurate and early diagnosis is an important first step in developing an effective management plan for your patients with HAE. Untreated HAE attacks can grow in intensity and may take longer to resolve.^2,4

Attacks in the larynx can be life-threatening, and they are especially dangerous for children who lack the ability to self-administer treatment during an attack or who may be unable to describe their symptoms.^2,3,5

TAKHZYRO is not indicated for acute treatment.

For both adult and pediatric patients, attacks can occur in the…³

Image of adult and child body figures pointing at the most common areas affected by HAE attacks.

The severity and frequency of HAE attacks may vary for each individual over time regardless of age, meaning that past attacks do not predict the severity of future attacks.⁶

Craft an Effective HAE Management Plan

Your patients' needs and disease may change over time, and they may need a reminder that their management plan can change.¹

All patients with HAE should have access to at least 2 doses of an acute medication in order to treat attacks when they happen¹
The 2020 HAEA guidelines recommend¹:
- Reviewing management plans for patients with HAE on a regular basis, including the need for preventive treatment¹
- TAKHZYRO as one of the first-line therapies for long term prevention for adult and adolescent patients ≥12 years of age^1,8

HAEA=Hereditary Angioedema Association

Help manage the impact of HAE on your patient's life—choose an effective management plan from diagnosis that helps to prevent and reduce HAE attacks.

What does effective prevention mean for patients?

Hear from patients taking TAKHZYRO.

View Transcript

SCOTT: Effective prevention means not just reducing the amount of HAE attacks I have, but also having to take TAKHZYRO just once every two weeks.

DENNIS: Effective prevention means it has the potential to reduce the frequency of my HAE attacks. With TAKHZYRO, not only am I having fewer attacks, but they're also less severe.

SORAYA: I used to have three HAE attacks a week and felt like I was spending half my life in the hospital. Now, I'm having periods of as long as two months with zero attacks, thanks to TAKHZYRO. Which is great because for me, even one attack is too many.

KELLY: Before preventive treatment, I felt like I could have an HAE attack at any moment. But in the last 12 months, I've only had one attack. That's incredible. I feel like now that I'm having fewer attacks, I've reached a new normal.

JACK: Years ago, HAE attacks forced me to quit my job. Reducing the frequency of my HAE attacks has helped me to focus on my career as a nurse.

ANDREW: Before I started preventive treatment, if I had an HAE attack, I would basically try my best to manage it in the moment. I would treat the swell reactively with my on-demand medicine and just wait for it to go down. Now that I'm taking TAKHZYRO, I know there's a way to help prevent my HAE attacks.

NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives.

NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions: pain, redness, and bruising; upper respiratory infection and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.

The US HAEA guidelines recommend TAKHZYRO as one of the first-line preventive therapy options for long-term prevention for adults and adolescents ≥12 years old¹

See takhzyro efficacy

What do the 2020 US HAEA Guidelines mean to patients?

See what patients taking TAKHZYRO think about their treatment being recommended by a trusted organization.

View Transcript

JACK: The HAEA is a nonprofit advocacy and research group that helps people with HAE and it's an organization that I trust. Their website is one of the first ones I tell people to visit if they want to learn about the condition.

KELLY: The HAEA worked with experts in the medical community to create HAE treatment recommendations. These guidelines recommend that everyone with HAE talk to their doctor about long-term preventive treatment in order to find out if it's right for them.

ANDREW: My HAE attacks weren't always frequent, but they could certainly be unpredictable. I thought it was enough to just take my on-demand medication when I needed it and just push through the attack. But talking to my doctor and understanding the guidance from the HAEA about long-term prevention really helped me turn a corner in how I manage my attacks.

SCOTT: The HAEA recommends TAKHZYRO as one of the first-line treatment options for long-term prevention of HAE attacks. That really means a lot to me because I respect the organization and it also makes me feel secure in my treatment choice.

DENNIS: It definitely gives me confidence knowing that they recommend TAKHZYRO as a preventive option. It means TAKHZYRO is one of the preventive treatments you should talk to your doctor about.

SORAYA: The HAEA recommendation makes me think I'm taking a medication that is recommended in the HAE community and I can feel good about that.

NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives.

NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions, pain, redness and bruising, upper respiratory infection, and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.

HAEA=Hereditary Angioedema Association.

The #1 prescribed HAE preventive treatment*

Imagine what the TAKHZYRO experience can mean for your patients

Long-term freedom from attacks for an average of 14.8 months in adult and adolescent patients^7†
Freedom from daily dosing: once every 2 weeks for patients 6 years of age and older, or every 4 weeks for patients 2 to 5 years of age⁸

Studied in over

200

Adult and pediatric patients across 3 studies⁸

Studied for up to

2.5

YEARS IN THE HELP OPEN-LABEL EXTENSION STUDY FOR ADULT AND ADOLESCENT PATIENTS⁸

Prescribed to over

3250

Patients since 2018^‡

^*Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.
^† Mean duration of the attack-free period in the open-label extension study was 14.8 (SD=12.4) months (N=209).¹
^‡ Based on third-party US specialty pharmacy data.

Explore the impact that TAKHZYRO may offer your patients, including the latest clinical data.

Explore educational events for
healthcare providers

Stay informed about the latest updates in the HAE community, with our series of in-person and virtual events led by professionals like you.

Find an hae event

TAKHZYRO is plasma-free and inhibits plasma kallikrein activity¹

See How It Works

Reference: 1. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 2. Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-336. doi:10.1016/j.anai.2013.08.019 3. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036. doi:10.1056/NEJMcp0803977 4. MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014;25(5):420-427. doi:10.1111/pai.12168 5. Johnston DT, Smith RC. Hereditary angioedema: special considerations in children. Allergy Asthma Proc. 2020;41(6)(suppl 1):S43-S46. doi:10.2500/aap.2020.41.200042 6. Bork K, Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. Eur Ann Allergy Clin Immunol. 2013;45(1):7-16. 7. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy. 2022;77(3):979-990. doi:10.1111/all.15011 8. Takhzyro. Prescribing information. Dyax Corp; 2023.

INDICATION

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.